FIT Biotech Oy
Company release 13.9.2018 klo 3:45 PM EET
FIT Biotech withdraws a patent application
FIT Biotech Ltd (“Company”, FITBIO: FN Finland) announced on 23rd of May 2018 that it filed two international patent applications. For strategic reasons, the board of directors of the company has decided to withdraw one of these applications before it is published. The withdrawn application relates to a further developed technology platform.
CEO Erkki Pekkarinen comments: “The patent application would have brought public such research results we want to keep private for strategic reasons.”
The company still has a pending patent application for the use of the company’s technology in the treatment of cancer. The application is very important as the company continues to commercialize gene-based therapies.
FIT BIOTECH OY
Board of Directors
Further information:
CEO Erkki Pekkarinen
Tel: +358 44 027 0080
E-mail: erkki.pekkarinen@fitbiotech.com
Certified Advisor: Aalto Capital Partners Oy, mobile +358 40 587 7000
FIT Biotech in brief
FIT Biotech Oy is a biotechnology company established in 1995 that develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies its GTU® technology in its development projects, which at the time include gene-based treatments, genetic vaccines and research collaboration. Application areas include cancer (gene therapy) and infectious diseases such as HIV.
FIT Biotech K-shares are listed on the First North Finland market maintained by Nasdaq Helsinki Ltd.
DISTRIBUTION:
Nasdaq Helsinki
Principal media
